Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

Abstract

Ovarian cancer is a multifaceted and genomically complex disease and has emerged as leading cause of death among gynecological malignancies. Gold-standard treatment consisted of cytoreductive surgery and paclitaxel-carboplatin chemotherapy. Recently, promising results of randomized trials have definitively confirmed the importance of angiogenesis in oncogenesis and ovarian cancer behavior, by showing a significant prolongation of progression-free survival with the addiction of an angiogenesis inhibitor to standard treatment in the first and second line setting. Research over the years has sequentially provided a rapidly broadening signaling landscape and many drugs targeting different signaling pathways of angiogenesis have been developed and investigated. Recently accumulating scientific evidence has started to shed light on the efficacy of AMG 386, a new peptibody reported to neutralize the interaction between angiopoietins (Ang1/2) and their Tie2 receptors, thus representing a promising alternative, both in terms of efficacy and toxicity profile and is considerably under investigation. The aim of this review is to summarize the recent researches and clinical progresses of AMG 386 as a novel target agent in ovarian cancer.

• Authors: Claudia Marchetti, Maria Luisa Gasparri, Ilary Ruscito, Innocenza Palaia, Giorgia Perniola, Angela Carrone, Ammad Ahmad Farooqi, Francesco Pecorini, Ludovico Muzii, Pierluigi Benedetti Panici
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 94 Issue 3 Pg. 302-10 (Jun 2015) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 25783620 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• Recombinant Fusion Proteins
• trebananib

Topics

• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Drug Evaluation, Preclinical
• Female
• Humans
• Molecular Targeted Therapy
• Neovascularization, Pathologic (drug therapy, metabolism)
• Ovarian Neoplasms (drug therapy, metabolism, mortality, pathology)
• Recombinant Fusion Proteins (pharmacology, therapeutic use)
• Treatment Outcome